Volume 32, No 12, Dec 2022
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 32 Issue 12, December 2022: 1036-1037
Off-the-shelf CAR T cells to treat cancer
Sofia Castelli , Regina M. Young , Carl H. June*Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
Chimeric antigen receptor (CAR) T cell therapies approved for cancer treatment are manufactured from a patient’s own cells (autologous), entailing challenges such as high costs, inconsistent product quality, and potential treatment failure due to T cell dysfunction. In a study published in Cell Research, Hu et al. generated CAR T cells from healthy donor T cells (allogeneic), and these were successful in a clinical trial for the treatment of T cell malignancies.